🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. same excipients except no hypromellose, PREDNISONE , SAR445761 - belumosudil, PREDNISOLONE

    Sanofi-aventis Healthcare Pty Ltd

    chronic graft versus host disease

    phase 3 small molecule active

    1 trial

  2. sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    6 trials

  3. sepofarsen

    ProQR Therapeutics N.V.

    Leber Congenital Amaurosis 10

    phase 3 small molecule active

    2 trials

  4. sotatercept, PL1 - Powder for injection

    Lacuna Pharma Pty Ltd

    Therapeutic confirmatory (phase III)

    phase 3 small molecule active

    1 trial

  5. sotatercept, sotatercept

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  6. sotrovimab

    Vir Biotechnology

    Covid19

    phase 3 mab terminated

    3 trials

  7. teclistamab, teclistamab, JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  8. three consecutive lots of EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 3 mab completed

    1 trial

  9. training kit, CHF1535 pMDI 100/6, CHF5993 pMDI-US

    Chiesi Farmaceutici S.p.A

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  10. tulisokibart, tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Ulcerative colitis

    phase 3 small molecule active

    1 trial

  11. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  12. ublituximab, DEXAMETHASONE, PARACETAMOL, GADOBUTROL, ublituximab placebo, DIPHENHYDRAMINE, CETIRIZINE, METHYLPREDNISOLONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  13. velaglucerase alfa

    Takeda

    Gaucher Disease, Type 1

    phase 3 mab completed

    1 trial

  14. vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)

    United Therapeutics Europe Ltd

    Mortality Through Six Months of Age

    phase 3 other completed

    1 trial

  15. vitamin D

    Takeda

    COVID-19

    phase 3 other completed

    1 trial

  16. volrustomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  17. zeleciment basivarsen (DYNE-101)

    Dyne Therapeutics

    Myotonic Dystrophy Type 1 (DM1)

    phase 3 small molecule active

    1 trial

  18. ziltivekimab, Placebo (ziltivekimab C)

    NovoThirteen

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial

  19. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  20. ​Placebo to Osimertinib - Film-coated tablet - 40mg / 80mg, CARBOPLATIN, TAGRISSO 80 mg film-coated tablets, CISPLATIN, PEMETREXED, PEMETREXED, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  21. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    tardive dyskinesia

    phase 2 small molecule active

    1 trial

  22. (+)-α-DIHYDROTETRABENAZINE

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  23. (+)-α-DIHYDROTETRABENAZINE, ADE513 placebo

    Lacuna Pharma Pty Ltd

    Tardive dyskinesia

    phase 2 small molecule active

    1 trial

  24. -

    Lacuna Pharma Pty Ltd

    Myocardial Infarction, Acute Heart Failure, Left Sided

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources